Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/dth.13743 http://scihub22266oqcxt.onion/10.1111/dth.13743 32478971!7300518!32478971     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Dermatol+Ther 2020 ; 33 (5): e13743 Nephropedia Template TP {{tp|p=32478971|t=2020. Psoriatic arthritis and COVID-19 pandemic: Consequences in medical treatment?|pdf=|usr=}}{{32478971}} gab.com Text Psoriatic arthritis and COVID-19 pandemic: Consequences in medical treatment JO: Dermatol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32478971 #FOAvip The COVID-19 pandemic has a strong negative impact on human society worldwide. Patients with immune-mediated disease may be prone to an increased risk of infection and/or more severe course. We review the available data for patients with psoriatic arthritis (PSA) and systemic treatments. Current treatment options are summarized. Based upon the experience with COVID-19, the following problems are addressed: (a) Can systemic treatment reduce comorbidities of PsA that are also comorbidities for COVID-19? Does systemic medical treatment pose an increased risk of infection with SARS-CoV-2? Does systemic drug therapy have an impact on the risk of pulmonary fibrosis-a factor with strong negative impact on COVID-19 outcome? Small molecules, inhibitors of tumor necrosis factor alfa, interleukin, and JAK inhibitors are considered. The data are inhomogeneous for the multiple drugs used in PsA. Although the risk for severe upper airway tract infections during clinical controlled trials was mostly in the range of placebo, these data have been obtained before the COVID-19 pandemic and should be interpreted with caution. Some biologics demonstrated an antifibrotic activity in vitro and in animal disease models. None of the biologics is indicated during an active infection with fever. In nonsymptomatic PsA patients, systemic drug therapy can be continued. Twit Text FOAVip Psoriatic arthritis and COVID-19 pandemic: Consequences in medical treatment ????Dermatol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32478971 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32478971 #FOAvip English Wikipedia <ref>{{Cite pmid|32478971}}</ref> Psoriatic arthritis and COVID-19 pandemic: Consequences in medical treatment? #MMPMID32478971 Wollina U; Fioranelli M; Goldust M; Lotti T Dermatol Ther 2020[Sep]; 33 (5): e13743 PMID32478971show ga The COVID-19 pandemic has a strong negative impact on human society worldwide. Patients with immune-mediated disease may be prone to an increased risk of infection and/or more severe course. We review the available data for patients with psoriatic arthritis (PSA) and systemic treatments. Current treatment options are summarized. Based upon the experience with COVID-19, the following problems are addressed: (a) Can systemic treatment reduce comorbidities of PsA that are also comorbidities for COVID-19? Does systemic medical treatment pose an increased risk of infection with SARS-CoV-2? Does systemic drug therapy have an impact on the risk of pulmonary fibrosis-a factor with strong negative impact on COVID-19 outcome? Small molecules, inhibitors of tumor necrosis factor alfa, interleukin, and JAK inhibitors are considered. The data are inhomogeneous for the multiple drugs used in PsA. Although the risk for severe upper airway tract infections during clinical controlled trials was mostly in the range of placebo, these data have been obtained before the COVID-19 pandemic and should be interpreted with caution. Some biologics demonstrated an antifibrotic activity in vitro and in animal disease models. None of the biologics is indicated during an active infection with fever. In nonsymptomatic PsA patients, systemic drug therapy can be continued. |*SARS-CoV-2[MESH] |Arthritis, Psoriatic/*drug therapy[MESH] |Biological Products/adverse effects[MESH] |COVID-19/*epidemiology/mortality[MESH] |Comorbidity[MESH] |Humans[MESH] |Janus Kinase Inhibitors/adverse effects[MESH]Psoriatic arthritis and COVID-19 pandemic: Consequences in medical tre(epmc).pdf DeepDyve Pubget Overpricing